Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Among authors: presas rodriguez s. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
Hervás-García JV, Ramió-Torrentà L, Brieva-Ruiz L, Batllé-Nadal J, Moral E, Blanco Y, Cano-Orgaz A, Presas-Rodríguez S, Torres F, Capellades J, Ramo-Tello C. Hervás-García JV, et al. Eur J Neurol. 2019 Mar;26(3):525-532. doi: 10.1111/ene.13851. Epub 2018 Nov 16. Eur J Neurol. 2019. PMID: 30351511 Clinical Trial.
Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.
Villarrubia N, Rodríguez-Martín E, Alari-Pahissa E, Aragón L, Castillo-Triviño T, Eixarch H, Ferrer JM, Martínez-Rodríguez JE, Massot M, Pinto-Medel MJ, Prada Á, Rodríguez-Acevedo B, Urbaneja P, Gascón-Gimenez F, Herrera G, Hernández-Clares R, Salgado MG, Oterino A, San Segundo D, Cuello JP, Gil-Herrera J, Cámara C, Gómez-Gutiérrez M, Martínez-Hernández E, Meca-Lallana V, Moga E, Muñoz-Calleja C, Querol L, Presas-Rodríguez S, Teniente-Serra A, Vlagea A, Muriel A, Roldán E, Villar LM. Villarrubia N, et al. Clin Chim Acta. 2019 Jan;488:135-142. doi: 10.1016/j.cca.2018.11.008. Epub 2018 Nov 5. Clin Chim Acta. 2019. PMID: 30408481
Gadolinium-enhanced brain lesions in multiple sclerosis relapse.
Martín-Aguilar L, Presas-Rodriguez S, Rovira À, Capellades J, Massuet-Vilamajó A, Ramió-Torrentà L, Tintoré M, Brieva-Ruiz L, Moral E, Cano-Orgaz A, Blanco Y, Batlle-Nadal J, Carmona O, Gea M, Hervás-García JV, Ramo-Tello C. Martín-Aguilar L, et al. Among authors: presas rodriguez s. Neurologia (Engl Ed). 2022 Sep;37(7):557-563. doi: 10.1016/j.nrleng.2021.10.005. Neurologia (Engl Ed). 2022. PMID: 36064284 Free article. Clinical Trial.
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.
Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A. Sepúlveda M, et al. Mult Scler. 2018 Dec;24(14):1843-1851. doi: 10.1177/1352458517735191. Epub 2017 Oct 6. Mult Scler. 2018. PMID: 28984163
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.
Granell-Geli J, Izquierdo-Gracia C, Sellés-Rius A, Teniente-Serra A, Presas-Rodríguez S, Mansilla MJ, Brieva L, Sotoca J, Mañé-Martínez MA, Moral E, Bragado I, Goelz S, Martínez-Cáceres E, Ramo-Tello C. Granell-Geli J, et al. Among authors: presas rodriguez s. J Pers Med. 2021 Dec 10;11(12):1347. doi: 10.3390/jpm11121347. J Pers Med. 2021. PMID: 34945819 Free PMC article.
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.
Sancho-Saldaña A, Gil Sánchez A, Quirant-Sánchez B, Nogueras L, Peralta S, Solana MJ, González-Mingot C, Gallego Y, Quibus L, Ramo-Tello C, Presas-Rodríguez S, Martínez-Cáceres E, Torres P, Hervás JV, Valls J, Brieva L. Sancho-Saldaña A, et al. Among authors: presas rodriguez s. J Clin Med. 2022 Apr 29;11(9):2509. doi: 10.3390/jcm11092509. J Clin Med. 2022. PMID: 35566632 Free PMC article.
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, Munteis E, Mansilla MJ, Presas-Rodriguez S, Navarro-Barriuso J, Ramo-Tello C, Martínez-Cáceres EM. Quirant-Sánchez B, et al. CNS Neurosci Ther. 2018 Dec;24(12):1175-1184. doi: 10.1111/cns.12851. Epub 2018 Apr 15. CNS Neurosci Ther. 2018. PMID: 29656444 Free PMC article.
Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.
Quirant-Sánchez B, Presas-Rodriguez S, Mansilla MJ, Teniente-Serra A, Hervás-García JV, Brieva L, Moral-Torres E, Cano A, Munteis E, Navarro-Barriuso J, Martínez-Cáceres EM, Ramo-Tello C. Quirant-Sánchez B, et al. Mediators Inflamm. 2019 Jun 26;2019:8147803. doi: 10.1155/2019/8147803. eCollection 2019. Mediators Inflamm. 2019. PMID: 31346315 Free PMC article.
Myelitis: Differences between multiple sclerosis and other aetiologies.
Presas-Rodríguez S, Grau-López L, Hervás-García JV, Massuet-Vilamajó A, Ramo-Tello C. Presas-Rodríguez S, et al. Neurologia. 2016 Mar;31(2):71-5. doi: 10.1016/j.nrl.2015.07.006. Epub 2015 Sep 14. Neurologia. 2016. PMID: 26383061 Free article. English, Spanish.
28 results